Topic: Parkinson's disease
As each company works to cut costs and stay alive, Acorda will lay off about one-quarter of its employees, while Alkermes will cut 160 jobs.
Stanford scientists have identified a molecular defect in Parkinson’s disease and pinpointed a promising drug candidate to target it.
Terazosin, a decades-old drug for enlarged prostate, appears to improve Parkinson's symptoms, tests in animal models and a large patient database show.
Boston Scientific’s deep brain stimulation implant for treating Parkinson’s disease has been approved by the FDA as safe to use within an MRI.
The series B will enable D&D subsidiary and Johns Hopkins spinout Neuraly to start phase 2 trials in Alzheimer's and Parkinson’s.
The deal will give Bayer control of an induced pluripotent stem cell pipeline led by a late-preclinical Parkinson’s disease candidate.
Research showing a protective role for the protein alpha-synuclein, which clumps up in some brain disorders, could inspire new treatments.
Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.
Researchers believe the models could shed light on how brain cells behave in these diseases and uncover new approaches to treat them.
Last month, Richard Peters was the chief executive of struggling Merrimack; today, he’s the new CEO at Fierce 15 winner Yumanity.